Skip to content

Prevalence of H.Pylori in Patients With Acne Vulgaris Acne Vulgaris

Prevalence of Helicobacter Pylori in Patients With Acne Vulgaris

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03411733
Enrollment
90
Registered
2018-01-26
Start date
2017-03-01
Completion date
2018-03-01
Last updated
2018-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne Vulgaris, Helicobacter Pylori Infection

Keywords

acne vlugaris, prevalence, Helicobacter Pylori

Brief summary

The objective of the study is to investigate prevalence of H.Pylori infection among acne vulgaris patients.

Detailed description

The study included patients with acne vulgaris and healthy control participants. The study recruited both sexes, all grades of acne, adolescents and young adults. All patients were subjected to complete history, general and skin examination Acne vlugaris Patients were classified into mild, moderate and severe according to the classification of American Academy of dermatology for acne vulgaris. Detection of H. pylori infection: Blood and stool samples were taken from each participant and was directly transferred to laboratory for detection of H. Pylori antigen and antibody. An enzyme-linked immune sorbent assay (ELISA) was used for quantitative assessment of IgG antibodies against H.Pylori in human serum. A monoclonal antibodies based enzyme-linked immunosorbent assay was used to detect H.Pylori specific antigen in stool samples.

Interventions

OTHERBlood and stool samples collection

Collection of blood and stool samples from each participants for H.pylori antigen/ antibody detection

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
12 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Acne vulgaris patients * Healthy volunteers (control)

Exclusion criteria

* Patients with a history of drug intake that affects H. Pylori such as proton-pump inhibitors, clarithromycin, tetracyclines, amoxicillin or metronidazole within previous two weeks were excluded.

Design outcomes

Primary

MeasureTime frameDescription
H.pylori infectionone yearPrevalence of H.pylori infection among acne group and control group

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026